Condition: Mesothelioma · Homologous Recombination Deficiency · Sponsor: University of Chicago
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
This description comes directly from the study's public registry record.
Hedy L Kindler, MD · 773-702-0360 · hkindler@medicine.bsd.uchicago.edu
Always discuss trial participation with your own doctor first.
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04515836